Axsome Therapeutics, Inc. $AXSM
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-310
RECRUITING7
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ENGAGE NCT06413433 |
P3 | Recruiting | Binge-Eating Disorder | 450 | 2026-12 (+12 mo) |
| Solriamfetol 150 mg NCT06568367 |
P3 | Recruiting | Excessive Sleepiness; Shift-work Disorder | 520 | 2026-12 |
| Solriamfetol NCT06878976 |
P3 | Enrolling by invitation | Binge-Eating Disorder | 236 | 2027-12 (+12 mo) |
| SUMMIT NCT07766655 |
P3 | Recruiting | Smoking Cessation | 705 | 2027-12 |
| Solriamfetol NCT07773883 |
P3 | Enrolling by invitation | ADHD | 300 | 2027-12 |
| FORWARD NCT07398417 |
P3 | Recruiting | Fibromyalgia | 620 | 2028-03 |
| AXS-14 (esreboxetine) NCT07637162 |
P3 | Enrolling by invitation | Fibromyalgia | 300 | 2028-05 |
| Solriamfetol Dose A NCT07717879 |
P3 | Recruiting | ADHD | 468 | 2028-06-30 |
| Solriamfetol Dose A NCT07717892 |
P3 | Recruiting | ADHD | 468 | 2028-06-30 |
| CLARITY NCT07484217 |
P3 | Recruiting | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | 508 | 2028-12 |